BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15076173)

  • 1. Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region.
    Rodgers A; Chapman N; Woodward M; Liu LS; Colman S; Lee A; Chalmers J; MacMahon S;
    J Hypertens; 2004 Mar; 22(3):653-9. PubMed ID: 15076173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
    PROGRESS Collaborative Group
    Lancet; 2001 Sep; 358(9287):1033-41. PubMed ID: 11589932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Arima H; Hart RG; Colman S; Chalmers J; Anderson C; Rodgers A; Woodward M; MacMahon S; Neal B;
    Stroke; 2005 Oct; 36(10):2164-9. PubMed ID: 16141420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee.
    J Hypertens; 1999 Nov; 17(11):1647-55. PubMed ID: 10608480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease.
    Ratnasabapathy Y; Lawes CM; Anderson CS
    Drugs Aging; 2003; 20(4):241-51. PubMed ID: 12641480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial.
    Fransen M; Anderson C; Chalmers J; Chapman N; Davis S; MacMahon S; Neal B; Sega R; Terent A; Tzourio C; Woodward M;
    Stroke; 2003 Oct; 34(10):2333-8. PubMed ID: 12958329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial.
    Chapman N; Huxley R; Anderson C; Bousser MG; Chalmers J; Colman S; Davis S; Donnan G; MacMahon S; Neal B; Warlow C; Woodward M;
    Stroke; 2004 Jan; 35(1):116-21. PubMed ID: 14671247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee.
    Chalmers J; Neal B; MacMahon S;
    J Hypertens Suppl; 2000 May; 18(1):S13-9. PubMed ID: 10939785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk.
    Ohkubo T; Chapman N; Neal B; Woodward M; Omae T; Chalmers J;
    Am J Respir Crit Care Med; 2004 May; 169(9):1041-5. PubMed ID: 14990394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS): interpretation and implementation.
    Chalmers J; MacMahon S
    J Hypertens Suppl; 2003 Jun; 21(5):S9-14. PubMed ID: 12953850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial.
    Berthet K; Neal BC; Chalmers JP; MacMahon SW; Bousser MG; Colman SA; Woodward M;
    Blood Press; 2004; 13(1):7-13. PubMed ID: 15083634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in reducing the burden of stroke.
    Chalmers J; Chapman N
    Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1091-5. PubMed ID: 11903323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. PROGRESS Management Committee.
    J Hum Hypertens; 1998 Sep; 12(9):627-9. PubMed ID: 9783492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROGRESS--perindopril protection against recurrent stroke study: status in July 1996. PROGRESS Management Committee.
    J Hypertens Suppl; 1996 Dec; 14(6):S47-51. PubMed ID: 9023716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PROGRESS--a trial on blood pressure lowering after stroke and TIA. ACE inhibitors and diuretics reduce the risk of new stroke].
    Terént A
    Lakartidningen; 2002 May; 99(20):2286-8, 2291. PubMed ID: 12082946
    [No Abstract]   [Full Text] [Related]  

  • 17. [ADVANCE study: objectives, design and current status].
    Chalmers J
    Drugs; 2003; 63 Spec No 1():39-44. PubMed ID: 12708881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trials on blood pressure-lowering and secondary stroke prevention.
    Chalmers J
    Am J Cardiol; 2003 May; 91(10A):3G-8G. PubMed ID: 12781902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease.
    PROGRESS Collaborative Group
    Eur Heart J; 2003 Mar; 24(5):475-84. PubMed ID: 12633548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADVANCE: breaking new ground in type 2 diabetes.
    Chalmers J; Perkovic V; Joshi R; Patel A
    J Hypertens Suppl; 2006 Aug; 24(5):S22-8. PubMed ID: 16936533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.